In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Zach TroyerDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-1821-7334 Miranda SoumakisDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Erin N ShirkDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Olesia GololobovaDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-0392-268X Sarah MarquezDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Martina FabianoLaboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.ORCID 0009-0007-5305-6904 Taekyung RyuCenter for Proteomics Discovery, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0009-0003-7850-804X Chan-Hyun NaCenter for Proteomics Discovery, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-3622-2938 Natalie CastellDepartment of Comparative Medicine, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Bastrop, Texas, USA.ORCID 0000-0002-0517-6131 Isabella BaumannDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0009-0000-0031-6898 Suzanne QueenDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0009-0001-7220-5254 Joseph L MankowskiDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-6283-4727 Kenneth W WitwerDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-1664-4233 Funding
Viral Testing CoreU42OD013117 · OD · JOHNS HOPKINS UNIVERSITY · PI JOSEPH L MANKOWSKI · 2017 to 2026
$10.9MExtracellular Vesicle and Extracellular RNA Biomarkers of HIV-1 Central Nervous System Pathogenesis and Cigarette UseR01DA047807 · NIDA · JOHNS HOPKINS UNIVERSITY · PI WITWER, KENNETH W · 2018 to 2022
$3.7MNovel Approaches to Capture, Sorting, and Characterization of CNS-Origin Extracellular VesiclesR33MH118164 · NIMH · JOHNS HOPKINS UNIVERSITY · PI MACHAIRAKI, VASILIKI, WITWER, KENNETH W · 2020 to 2022
$2.2MNovel Separation Methods for exRNA Carriers: Extracellular Vesicles, Lipoprotein Particles, and Protein AggregatesUH3CA241694 · NCI · JOHNS HOPKINS UNIVERSITY · PI WITWER, KENNETH W · 2021 to 2022
$1.1MNovel Separation Methods for exRNA Carriers: Extracellular Vesicles, Lipoprotein Particles, and Protein AggregatesUG3CA241694 · NCI · JOHNS HOPKINS UNIVERSITY · PI WITWER, KENNETH W · 2019 to 2020
$941kNovel Approaches to Capture, Sorting, and Characterization of CNS-Origin Extracellular VesiclesR21MH118164 · NIMH · JOHNS HOPKINS UNIVERSITY · PI MACHAIRAKI, VASILIKI, WITWER, KENNETH W · 2018 to 2019
$471kNCI NIH HHS UG3 CA241694NCI NIH HHS UH3 CA241694NIDA NIH HHS R01 DA047807NIH HHS U42 OD013117NIMH NIH HHS R21 MH118164NIMH NIH HHS R33 MH118164
6 · The paper itselfAbstract
Extracellular vesicles (EVs) are versatile therapeutic candidates due to biological roles in intercellular communication and amenability to bioengineering. Compared with lipid nanoparticles (LNPs), native or surface-modified EVs may have favorable immunogenicity and biodistribution profiles. However, when administered intravenously (IV), EVs are rapidly cleared and accumulate mostly in the liver and spleen. With the goal of modifying EV biodistribution, we engineered EVs to display the human endogenous retrovirus (HERV) envelope glycoprotein Syncytin-1, an SLC1A5-binding fusogenic viral protein essential for syncytiotrophoblast formation in pregnancy. Here, we comprehensively characterize engineered Syncytin-1+ EVs, examine their interactions with cells
Identifiers
PMID42146402
PMCPMC13174609
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390